Since the first patient with dementia described by Alois Alzheimer in 1907, many therapeutic strategies for AD have been proposed: acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, anti-amyloid therapies, drugs targeting tau protein and mitochondrial dysfunction, and so on [4]. This evidence concerns the gene MAPT and Alzheimer disease.